Induced Membrane Properties in Children and Adults
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Jan 28, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
**Summary of the Clinical Trial: Induced Membrane Properties in Children and Adults**
This clinical trial is studying a new way to help heal bone injuries that are too large to heal on their own, known as critical sized defects. The Masquelet technique, which is being researched, involves a two-step process. First, a special spacer is placed in the bone defect, which helps the body form a natural membrane around it. After some time, the spacer is removed, and the area is filled with bone graft material to support healing. Researchers want to learn more about how this membrane helps with blood flow and bone healing in both children and adults.
If you or a family member have a critical sized bone defect and are between the ages of 9 months and 60 years, you might be eligible to participate in this study at CHU Amiens-Picardie. However, those who are pregnant, nursing, or have other issues like being under guardianship can't join. Participants will be closely monitored throughout the study to understand how well this technique works. It's an opportunity to contribute to important research that could improve bone healing methods in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients treated at CHU Amiens-Picardie for bone critical sized defect treated using the induced membrane reconstruction technique.
- • patients from 9 months to 60 years old
- Exclusion Criteria:
- • Patients managed by another reconstruction technique for critical sized defect
- • Patients under guardianship, curators or deprived of liberty.
- • Pregnant and nursing women.
- • Patients who refused to participate in the study and to sign informed consent.
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Trial Officials
Céline Klein, MD
Principal Investigator
CHU Amiens
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials